Lv6
2230 积分 2022-09-04 加入
Response to Lavin et al (2025)’s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
18天前
已关闭
Trastuzumab-induced optic neuritis: “blindness” side effect
1个月前
已完结
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
5个月前
已完结
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
5个月前
已完结
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial
5个月前
已完结
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders
5个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
8个月前
已完结
Anti–Interleukin-23 Autoantibodies and Severe Infections
9个月前
已完结
皖公网安备34019202002308
